BillionToOne, Inc. reported second quarter 2026 financial results on August 5, 2026, showing total revenue of $109.4 million, a 64% increase from the prior year period. Prenatal clinical testing revenue rose 55% to $94.2 million, while oncology clinical testing revenue surged 176% to $13.7 million. The company delivered 196,000 tests and achieved a gross profit margin of 70%, up from 65% in the previous year. Operating income turned positive at $5.5 million compared to a $1.6 million loss in the prior year period, resulting in net income of $8.1 million or $0.15 per diluted share. BillionToOne reiterated its full-year 2026 revenue guidance of $450 million to $465 million and announced upcoming product launches for its Unity Fetal Risk Screen and Northstar Origin test. The company operates in the molecular diagnostics industry, developing and commercializing genetic testing services.

BillionToOne, Inc. entered into a 12-year lease agreement with Whipple Road Portfolio, LLC for approximately 62,659 square feet of office and laboratory space in Union City, CA. The lease, which is expected to attach on August 1, 2027, involves an aggregate base rent of approximately $46.7 million over the term, with a $12.5 million tenant improvement allowance and a 12-month rent abatement. BillionToOne, Inc. is a biotechnology company providing oncology-focused diagnostic tests.